Abstract:Background Selenium is an essential trace element in the human body. In epidemiological and clinical studies, Se supplementation significantly reduced the incidence of lung cancer in individuals with low baseline Se levels. The significant action of selenium is based on the selenium‐containing protein as a mediator. Of note, the previous studies reported that the expression of selenium‐binding protein 1 (SELENBP1) was obviously decreased in many human cancer tissues including non‐small cell lung cancer (NSCLC). However, its roles in the origin and development of NSCLC are still unclear. Methods The expression of SELENBP1 was measured by qRT‐PCR, Western blotting and IHC in our collected clinical NSCLC tissues and cell lines. Next, the CCK‐8, colony formation, wound‐haeling, Millicell, Transwell, FCM assay, and in vivo xenograft model were performed to explore the function of SELENBP1 in NSCLC. The molecular mechanisms of SELENBP1 were investigated by Western blotting or IF assay. Results We further identified that the expression of SELENBP1 was significantly decreased in NSCLC tissues in TCGA database and 45 out of 59 collected clinical NSCLC tissues compared with adjacent nontumor tissues, as well as in four NSCLC cell lines compared with normal lung cells. Particularly, we unexpectedly discovered that SELENBP1 was obviously expressed in alveolar type 2 (AT‐II) cells for the first time. Then, a series of in vitro experiments uncovered that overexpression of SELENBP1 inhibited the proliferation, migration, and invasion of NSCLC cells, and induced cell apoptosis. Moreover, overexpression of SELENBP1 also inhibited growth and induced apoptosis of NSCLC cells in vivo. Mechanistically, we demonstrated that overexpression of SELENBP1 inhibited the malignant characteristics of NSCLC cells in part via inactivating the PI3K/AKT/mTOR signal pathway. Meanwhile, we found that overexpression of SELENBP1 inducing the apoptosis of NSCLC cells was associated with the activation of caspase‐3 signaling pathway under nonhigh level of oxidative stress, but overexpression of SELENBP1 facilitating the cell apoptosis might be related to its combining with GPX1 and colocalizing in the nucleus under high level of oxidative stress. Conclusions Our findings highlighted that SELENBP1 was an important tumor suppressor during the origin and development of NSCLC. It may help to discover novel biomarkers or drug therapy targets for NSCLC.

SELENBP1 Inhibits the Warburg Effect and Tumor Growth by Reducing the HIF1α Expression in Colorectal Cancer

SELENBP1 Inhibits Progression of Colorectal Cancer by Suppressing Epithelial–mesenchymal Transition

Selenium binding protein 1 inhibits tumor angiogenesis in colorectal cancers by blocking the Delta-like ligand 4/Notch1 signaling pathway

Selenium-Binding Protein 1 May Decrease Gastric Cellular Proliferation And Migration

Downregulation of SELENBP1 Enhances Oral Squamous Cell Carcinoma Chemoresistance Through KEAP1–NRF2 Signaling

Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer

Selenium‐binding protein 1 inhibits malignant progression and induces apoptosis via distinct mechanisms in non‐small cell lung cancer

Suppression of cellular apoptosis susceptibility (CSE1L) inhibits proliferation and induces apoptosis in colorectal cancer cells.

HES1 Promotes Aerobic Glycolysis and Cancer Progression of Colorectal Cancer Via IGF2BP2-mediated GLUT1 M6a Modification

Transcriptional Regulation and Biological Functions of Selenium-Binding Protein 1 in Colorectal Cancer in Vitro and in Nude Mouse Xenografts

Selenite inhibits glutamine metabolism and induces apoptosis by regulating GLS1 protein degradation via APC/C-CDH1 pathway in colorectal cancer cells.

Quantitative proteomic analysis reveals that anti-cancer effects of selenium-binding protein 1 in vivo are associated with metabolic pathways.

GLS1 depletion inhibited colorectal cancer proliferation and migration via redox/Nrf2/autophagy-dependent pathway

Up-regulated SLC25A39 promotes cell growth and metastasis via regulating ROS production in colorectal cancer

RRS1 Silencing Suppresses Colorectal Cancer Cell Proliferation and Tumorigenesis by Inhibiting G2/M Progression and Angiogenesis

Sa1711 – Bone Marrow-Derived Myofibroblasts Promotes Gastric Cancer Metastasis Through Activating TGF-Β1 and Il-6/Stat3 Signal Pathways

The P38 MAPK-regulated PKD1/CREB/Bcl-2 Pathway Contributes to Selenite-Induced Colorectal Cancer Cell Apoptosis in Vitro and in Vivo.

SELENOF is a new tumor suppressor in breast cancer

Selenoprotein S (SELENOS) is a potential prognostic biomarker for brain lower grade glioma

Selenoprotein S regulates tumorigenesis of clear cell renal cell carcinoma through AKT/ GSK3β/NF-κB signaling pathway

Sa1709 – Targeting Dr5 in Both Mdscs and Gastric Cancer Cells Enhances Anti-Pd-L1 Antibody Immunotherapy Efficacy in a Gastric Cancer Murine Model